- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03368729
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Erica Stringer-Reasor, M.D.
- Phone Number: 205-975-2816
- Email: strinem@uab.edu
Study Contact Backup
- Name: Eddy Yang, M.D., Ph.D.
- Phone Number: 205-934-2762
- Email: eyang@uab.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama At Birmingham
-
Contact:
- Erica Stringer-Reasor, M.D.
- Phone Number: 205-975-2816
- Email: strinem@uab.edu
-
Contact:
- Pamela Hardwick
- Phone Number: 205-975-5387
- Email: pamdixon@uab.edu
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Principal Investigator:
- Rita Nanda, MD
-
Contact:
- Rita Nanda, MD
- Phone Number: 773-834-7756
- Email: rnanda@medicine.bsd.uchicago.edu
-
Contact:
- Chloe Kuhn
- Phone Number: 773-702-1220
- Email: ckuhn1@medicine.bsd.uchicago.edu
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Not yet recruiting
- Mayo Clinic
-
Contact:
- Minetta Liu, MD
- Email: Liu.Minetta@mayo.edu
-
Contact:
- Adrienne Benson
- Phone Number: 507-284-3045
- Email: benson.adrienne@mayo.edu
-
Principal Investigator:
- Minetta Liu, MD
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore
-
Contact:
- Jesus Anampa, MD
- Phone Number: 718-405-8404
- Email: JANAMPA@montefiore.org
-
Contact:
- Ana Maria Guarin
- Phone Number: 718-405-8428
- Email: abernal@montefiore.org
-
Principal Investigator:
- Jesus Anampa, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- University of North Carolina
-
Contact:
- Claire Dees, MD
- Phone Number: 919-842-7714
- Email: Claire_dees@med.unc.edu
-
Contact:
- Tamara Pfeffer, RN BSN
- Email: tamara_pfeffer@med.unc.edu
-
Principal Investigator:
- Claire Dees, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Not yet recruiting
- University of Pennsylvania
-
Principal Investigator:
- Amy Clark, MD
-
Contact:
- Amy Clark, MD
- Email: Amy.Clark@pennmedicine.upenn.edu
-
Contact:
- Noah Goodman, MPH
- Phone Number: 215-260-8518
- Email: noah.goodman@pennmedicine.upenn.edu
-
-
Washington
-
Seattle, Washington, United States, 98109
- Recruiting
- University of Washington-
-
Contact:
- Jennifer Specht, MD
- Phone Number: 206-606-2053
- Email: jspecht@uw.edu
-
Contact:
- Sya Magee
- Phone Number: (206) 606-6424
- Email: smagee@seattlecca.org
-
Principal Investigator:
- Jennifer Specht, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women age ≥ 18 years
- Eastern Cooperative Oncology Group performance status 0-2 (Karnofsky >60%).
- Patients with metastatic breast cancer.
- HER2 (human epidermal growth factor receptor 2)-positive breast cancer prospectively determined on the primary tumor by a local pathology laboratory and defined as: Immunohistochemistry (IHC) score of 3+ and/or positive by ISH (defined by In Situ Hybridization ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies). Both IHC and ISH assays will be performed; however, only one positive result is required for eligibility.
- Estrogen/progesterone receptor positive OR negative disease allowed.
- Patients must have measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Patients that have failed at least one anti-HER2 therapy in the metastatic setting.
Patients must have normal organ and marrow function as defined below:
- absolute neutrophil count ≥1,500/mL
- platelets ≥100,000/mL
- total bilirubin ≤ institutional upper limit of normal (ULN)
- aspartate aminotransferase (AST)/alanine aminotransferase (ALT) 5 ≤ X institutional ULN
- creatinine ≤ institutional ULN OR creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal.
- Baseline left ventricular ejection fraction (LVEF) ≥ 50% measured by echocardiogram (preferred) or multigated acquisition (MUGA) scans.
- Willing and able to comply with the requirements of the protocol.
- Patient is able to take oral medication.
- Signed informed consent.
- Female patients of childbearing potential must be willing to use one highly effective form of hormonal contraception or two effective forms of nonhormonal contraception.
Contraception must continue for the duration of study treatment and for 7 months after the last dose of study treatment. The above contraception is not a requirement in the case of any of the following:
- The patient, or partner of the patient, is surgically sterilized.
- The female patient is >45 years of age and is postmenopausal (has not menstruated for at least 12 consecutive months
- The patient truly abstains from sexual activity and when this is the preferred option to avoid conception and contraception and/or usual lifestyle of the patient.
Exclusion Criteria:
- Metastatic breast cancer patients who are HER2 positive and have NOT progressed on at least one prior HER2-targeted therapies for metastatic disease
- Patients who have not recovered from CTCAE, v. 4.03 grade 2 or higher toxicities of prior therapy to the point that they would be appropriate for re-dosing will be ineligible for study treatment. Subjects receiving weekly therapy must have a washout period from prior chemotherapy of as least one week. Washout period for chemotherapy administered every 2, 3, or 4 weeks will be 2, 3, and 4 weeks respectively, provided subject has recovered from toxicities of prior therapy such that retreatment is appropriate.
- Patients must be at least two weeks from prior RT
- Patients must have a one-week washout period from prior hormonal therapy (e.g. testosterone, estrogen, progestin, gonadotropin-releasing hormone antagonist).
- Patient has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a patient from study participation regardless of clinical stability.
No concurrent anti-cancer treatment of any type
- Patients with known germline BRCA 1 or BRCA 2 mutations
- Patient has undergone prior treatment with a known poly(ADP-ribose) polymerase (PARP) inhibitor.
- Prior treatment of a total doxorubicin >360 mg/m2 (or equivalent)
- Patient has known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [HCV RNA] [qualitative] is detected).
- Patient has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
- Chronic immunosuppressive therapies including systemic corticosteroids or concurrent short-term use of immunosuppressive therapies is not allowed. Short- term corticosteroid use must be discontinued at least 2 weeks prior to study treatment.
- Patients with known grade 2 or greater allergic reactions attributed to compounds of similar chemical or biological composition to niraparib are ineligible for study enrollment.
- Patients with known grade 2 or greater allergic reactions attributed to compounds of similar chemical or biological composition to herceptin are ineligible for study enrollment.
- Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 7 months after the last dose of study treatment.
History of non-breast malignancies within the 5 years prior to study entry, except for the following:
- Carcinoma in situ (CIS) of the cervix
- CIS of the colon
- Melanoma in situ
- Basal cell and squamous cell carcinomas of the skin
- Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).
Cardiopulmonary dysfunction as defined by any of the following prior to randomization:
- History of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.0) Grade ≥3 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) criteria Class ≥ II
- Angina pectoris requiring anti-angina medication, serious cardiac arrhythmia not controlled by adequate medication, severe conduction abnormality, or clinically significant valvular disease
- High-risk uncontrolled arrhythmias (i.e. atrial tachycardia with a heart rate >100/min at rest, significant ventricular arrhythmia [ventricular tachycardia], or higher-grade atrioventricular [AV]-block [second degree AV-block Type 2 [Mobitz 2] or third degree AV-block])
- Significant symptoms (Grade ≥2) relating to left ventricular dysfunction, cardiac arrhythmia, or cardiac ischemia
- Myocardial infarction within 12 months prior to randomization
- Uncontrolled hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg)
- Evidence of transmural infarction on ECG
- Heart-rate corrected QT interval (QTc) prolongation >470 msec at screening.
- Requirement for oxygen therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg
In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
|
Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
Other Names:
Trastuzumab is a commercially available agent administered by intravenous infusion.
A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
|
Experimental: Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg
In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
|
Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
Other Names:
Trastuzumab is a commercially available agent administered by intravenous infusion.
A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
|
Experimental: Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg
The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1.
A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1.
If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
|
Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
Other Names:
Trastuzumab is a commercially available agent administered by intravenous infusion.
A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 1: Dose-limiting toxicity (DLT)
Time Frame: Baseline to 6 weeks
|
A DLT is defined as hematological events > or equal to grade 3 leukopenia, anemia, and thrombocytopenia and also non-hematological events > or equal to grade 3 fatigue, nausea, constipation, vomiting, or diarrhea.
|
Baseline to 6 weeks
|
Phase 2: Objective Response Rate
Time Frame: Baseline up to 100 weeks
|
Response and progression of disease will be evaluated using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Committee.
|
Baseline up to 100 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events
Time Frame: Baseline up to 100 weeks
|
Toxicities will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03.
|
Baseline up to 100 weeks
|
Progression-free survival
Time Frame: Baseline to the date of first documented progression to date of death from any cause, whichever comes first, assessed up to 100 months
|
The RECIST v. 1.1 criteria will be used to evaluate progression-free survival as well as CT and MRI scans.
Progression is indicative of existing target and non-target lesions.
|
Baseline to the date of first documented progression to date of death from any cause, whichever comes first, assessed up to 100 months
|
Phase 1: Niraparib levels
Time Frame: Baseline to 25 days
|
Plasma niraparib levels will be assessed at specific time points in participants blood during cycle 2 treatment in Phase I patients only.
A population pharmacokinetic modeling approach will be used to describe area under the curve (AUC) plasma concentrations of niraparib and its metabolites in participants in this study.
|
Baseline to 25 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Erica Stringer-Reasor, M.D., University of Alabama At Birmingham
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- F2017000 (UAB 17112)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
Clinical Trials on Niraparib
-
Tesaro, Inc.Completed
-
Virginia Commonwealth UniversityGlaxoSmithKline; Puma Biotechnology, Inc.RecruitingOvarian Cancer | Advanced Solid TumorUnited States
-
Tesaro, Inc.Active, not recruiting
-
Fudan UniversityRecruitingTreatment EfficacyChina
-
Chongqing University Cancer HospitalRecruiting
-
Abramson Cancer Center at Penn MedicineActive, not recruitingProstate AdenocarcinomaUnited States
-
Hunan Cancer HospitalUnknown
-
German Breast GroupGlaxoSmithKline; Stemline Therapeutics, Inc.Not yet recruitingBRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast CancerGermany
-
Sun Yat-sen UniversityRecruitingNasopharyngeal CarcinomaChina
-
Lei LiRecruitingChemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian CancerChina